bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
bioAffinity Technologies partnered with Pictor, Inc. to develop and commercialize next-generation diagnostics for asthma and COPD, integrating bioAffinity’s flow cytometry with Pictor’s proteomic analysis platform. The collaboration aims to lower operating costs and improve laboratory efficiency to serve a market projected to exceed $108 billion by 2026.
Key figures
- Market size 2026 usd
- 108000000000
- Market size 2030 usd
- 155000000000
- Addressable population us
- 40000000
- Addressable population global
- 650000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.